Contrast in the Time of Cardio-Oncology – SDMS – 2025

In this webinar we discuss the when and why to use ultrasound enhancing agents (UEAs). This includes when two or more LV segments cannot be visualized adequately for the assessment of LV function (LVEF and RWM assessment) and/or in settings in which the study indication requires accurate analysis of RWMA (JASE 2018). Current information on safety and optimization is discussed and we explore Cardio-Oncology and how best to monitor cardiotoxicity. Lastly, we cover current updates of UEA roles in the evaluation of masses including perfusion techniques.

1. When, why, and how should I use ultrasound enhancing
   agents?
   
   1. Current recommendations
   2. Safety
   3. Optimization
2. Cardio-Oncology
   
   1. What is it? Why is it important?
   2. What imaging should I use to monitor for cardiotoxicity?
      
      • 2D, 3D, ultrasound enhancing agents
   3. Usefulness of Strain
3. UEA for mass perfusion
   
   1. Thrombus vs Tumor?
   2. Optimizing perfusion techniques

This program has been designed for sonographers, and other healthcare professionals involved in echocardiography.

Rupal O’Quinn, MD, FACC

Director of Cardio-Oncology
Penn Presbyterian Medical Center
Assistant Professor of Clinical Medicine
Perelman School of Medicine
University of Pennsylvania

Michelle McGovern, RDCS

Echocardiography Lab Technical Director
Perelman Center for Advanced Medicine
Hospital of the University of Pennsylvania